3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Fluorouracil
61
Leucovorin
56
Oxaliplatin
51
Capecitabine
42
Irinotecan
29
Bevacizumab
21
Radiotherapy
17
Cetuximab
12
Folfox protocol
11
Chemoradiotherapy
11
Neoadjuvant Therapy
10
Chemotherapy, Adjuvant
9
Surgical Procedures, Operative
6
Drug Therapy
6
XELOX
5
Panitumumab
4
Laparoscopy
4
FOLFOXIRI protocol
4
Transanal Endoscopic Microsurgery
3
Radiation
3
Octreotide
3
IFL protocol
3
Floxuridine
3
Diathermy
3
Celecoxib
3
vatalanib
2
spartalizumab
2
Trinitrotoluene
2
Tegafur
2
Semaxinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Rectal Neoplasms
×
adagrasib
×
Clear all
NCT04793958
2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3
Active not recruiting
461 enrolled